Licencias y transferencia de tecnología

Leverage our portfolio of 20+ Class III medical devices, including NMPA-approved innovations and CE-pending technologies, to build your competitive edge through flexible collaboration frameworks in your local area.

Joint Registration

Co-develop and co-regulate products in target markets.
We provide technology and pre-clinical/clinical data;
Our partner contributes local regulatory expertise and resources.
We Thrive with Partners Who have:

Proven success in international medical device approvals

Capabilities to support region-adapted clinical validation

Cross-border regulatory network resources

Platform Technology Transfer

Acquire complete biomaterial platforms (e.g., polymer microspheres, dECM) for autonomous product development.
Flexible collaboration frameworks in your local area.
We Thrive with Partners Who have:

Advanced manufacturing infrastructure (ISO 13485+)

R&D capacity for technology evolution

Vision to expand regenerative medicine portfolios

Exclusive Regional Distribution

Obtain exclusive rights to market approved products in your territory.
We handle manufacturing and shipment to partner’s warehouse
Our partner manages sales channels and local market penetration.
We Thrive with Partners Who have:

Remarkable market presence in aesthetic/medical distribution

Capabilities to support region-adapted clinical validation

Cross-border regulatory network resources

New-co Venture

Co-establish a new entity for targeted markets/products.
We contribute IP tech;
Our partner provides capital commercialization infrastructure;
Equity-based collaboration.
We Thrive with Partners Who have:

Bring significant healthcare investment expertise

Possess portfolio synergies in medical aesthetics

Execute with operational agility

Togehter, let’s architect your global aesthetics leadership strategy.

Latest News

Xihong Biopharma and So Young Technology Form Deep Strategic Partnership to Shape the Future of Regenerative Medicine in Anti-Aging

July.06.2023

The parties have entered into a 10-year exclusive master distribution agreement covering two advanced aesthetic products: the Sodium Hyaluronate Injectable Complex Solution and a new-generation Injectable PLLA Microsphere Facial Filler.

Xihong Biopharma Grants Exclusive License to CMS for Injectable PLLA Filler

July.10.2025

The injectable poly-L-lactic acid (PLLA) microsphere filler is classified as a Class III medical device and is currently undergoing registrational clinical trials in China. The product utilizes a patented microsphere fabrication process, resulting in uniformly shaped microspheres with even subcutaneous distribution and outstanding clinical performance.

Xihong Biopharma Wraps Up a Successful Showcase at AMWC 2025 Monaco

March.29.2025

Xihong Biopharma showcased its regenerative medicine solutions—combining advanced science, innovative manufacturing, and global partnerships. As a leading innovator from China, Xihong impressed attendees with its deep expertise and comprehensive portfolio in regenerative aesthetics.

About Us: About Xihong; Manufacturing and R&D; OEM & ODM; Licensing & Technology Transfer

All Products: Dermal Filler; Materials & Microspheres; PLLA; CaHA

CONTACT: No. 20, Wenzhou Road, National Economic Development Zone, Shuyang, Suqian, Jiangsu Province; coop@dfyanmei.com; +8613310882353

Follow Us

Leave a message

First Name*

Last Name*

Email*

Message*